Company: SUNE
Filing Date: 2025-02-27
Form Type: 424B5
Source: 0001213900-25-017771
Chunk: 15

Company: SUNation Energy, Inc.
Filing Date: 2025-02-27
Form: 424B5
Chunk 15
---
 in our quarterly reports on Form 10-Q and our current reports on Form 8-K, as well as any amendments thereto reflected in subsequent filings, each of which are incorporated by reference herein. Additional risks we are not presently aware of or that we currently believe are immaterial or very preliminary may also impair our business operations, financial condition or results of operations. Our business, financial condition or results of operations could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. In assessing these risks, you should also refer to the risk factors and other information contained or incorporated by reference into this prospectus supplement, and the accompanying prospectus, specifically including the risk factors contained in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and Current Report on Form 8-K, as filed with the SEC, which are incorporated in this prospectus by reference in their entirety, as well as any amendment or updates to our risk factors reflected in subsequent filings with the SEC, including any free writing prospectus that we may authorize for use in connection with this offering. You should also see our risk factors included in our prospectus supplement filed on January 7, 2025 regarding our previously announced Bitcoin strategy, which remain applicable unless and until we formally determine to abandon or terminate such related investment options.

Risks Related to This Offering

Stockholders may suffer substantial dilution if certain provisions in the common warrants are utilized.

The common warrants contain exercise price adjustments
and, in the case of the Series B Warrants, an alternative cashless exercise feature, which, if triggered, may cause substantial dilution.

Following the Warrant Stockholder Approval,
if the Event Market Price is less than the exercise price of the Series A Warrants or Series B Warrants, respectively, then the
exercise price will be reduced to the Event Market Price and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate price will remain unchanged, provided, however, the adjusted exercise price shall not be less than the
Floor Price.

In addition, if, while the common warrants are
outstanding, we issue or sell, or are deemed to have issued or sold, any common stock and/or common stock equivalents other than in connection
with certain exempt issuances, at a purchase price per share less than the exercise price of the common warrants in effect immediately
prior to such issuance or sale or deemed issuance